(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 April 2010 (15.04.2010)

PCT

(10) International Publication Number
WO 2010/040979 A1

(51) International Patent Classification:
A61M 15/08 (2006.01)

(21) International Application Number:
PCT/GB2009/002288

(22) International Filing Date:
28 September 2009 (28.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0818396.4 8 October 2008 (08.10.2008) GB

(71) Applicant *(for all designated States except US)*: **ARCHIMEDES DEVELOPMENT LTD.** [GB/GB]; Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG2 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CASTILE, Jonathan** [GB/GB]; Archimedes Development Limited, Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB). **WATTS, Peter** [GB/GB]; Archimedes Development Limited, Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB). **SMITH, Alan** [GB/GB]; Archimedes Development Limited, Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB).

(74) Agent: **JOHNSTONE, Helen**; POTTER CLARKSON LLP, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: A DEVICE FOR ADMINISTERING LIQUID ANALGESICS



Fig. 1

(57) **Abstract**: In the field of pain relief and treatment there is a need for a device which is able to administer several predetermined doses of an opioid analgesic in a manner which can be done simply and safely by a patient or carer; in particular in a manner which minimises the risk of administering too great a dose at any one time. A device (10), for administering a predefined number (N) of predefined volume unit doses (Vu) of an opioid analgesic in liquid form, includes a closed container (12) which contains a predetermined fill volume (Vf) of the opioid analgesic, and a dispenser (14) that is connected to the container (12). The dispenser (14) is operable to administer an individual one volume unit dose (Vu) repeatedly said predefined number of times (N). Both the dispenser (14) is adapted, and the concentration of said opioid analgesic is chosen such that said volume unit dose is in the range 0.05 to 0.15ml.

WO 2010/040979 A1

A DEVICE FOR ADMINISTERING LIQUID ANALGESICS

The present invention relates to a device for administering, in particular but not exclusively, opioid analgesics for the relief and treatment of pain.

The invention is particularly concerned with administration in the form of a spray such as in the intranasal, buccal or sublingual administration of drugs, or more particularly the intranasal administration of opioid analgesics.

Opioid analgesics are currently the most pharmacologically effective means of alleviating severe pain. Examples include morphine, diamorphine, codeine, hydromorphone, oxymorphone, oxycodone, meperidine, fentanyl, sufentanil, remifentanil and alfentanil.

Intranasal administration of opioid analgesics is especially advantageous since it provides the potential for very rapid treatment of acute pain since the drug molecule will rapidly pass from the nasal passages into the systemic circulation.

Although such rapid treatment is advantageous when the analgesic is used properly, it can be extremely hazardous to the health of a patient if the analgesic is accidentally or deliberately misused. For example misuse could lead to life threatening side effects, in particular respiratory depression.

As a consequence there are many legal and regulatory controls over the distribution, prescription and use of opioid analgesics.

For many therapeutic applications it is necessary to administer opioid analgesics several times throughout a day.

Bearing in mind the consequences of administering the opioid analgesic incorrectly, it will be appreciated that it is highly desirable to provide for the administration of several predetermined doses of an opioid analgesic in a manner which can be done simply and safely by a patient or carer; in particular in a manner which minimises the risk of administering too great a dose at any one time.

It is a general object of the present invention to provide a device for administration of an opioid analgesic in accordance with the aims set out above.

According to one aspect of the present invention there is provided a device for administering a predefined number (N) of predefined volume unit doses (Vu) of an opioid analgesic solution, the device including a closed container containing a predetermined fill volume (Vf) of the opioid analgesic solution and a dispenser connected to the container, the dispenser being operable to administer an individual one volume unit dose (Vu) repeatedly said predefined number of times (N), both the dispenser being adapted and the concentration of said opioid analgesic in said solution being chosen such that said volume unit dose is in the range 0.05 to 0.15ml.

Preferably the volume unit dose is 0.1ml.

Typically, the concentration of the opioid analgesic in liquid form is in the range of 0.005 to 1000 mg/ml.

Optionally the opioid analgesic is a solution of fentanyl, the concentration of the fentanyl in the solution being in the range 0.1 to 20 mg/ml.

Preferably the opioid drug solution is a solution of fentanyl citrate, the concentration of fentanyl citrate in the solution being in the range of about 0.16 to 31.4 mg/ml.

The choice of the opioid solution as defined above which is dispensed in a volume unit dose in the range 0.05 to 0.15ml enables the device to be used to administer say one or maybe two volume unit doses at any one time to provide effective treatment. This means that at any one treatment time, the patient will be administered with either one volume unit dose into one nostril, or one volume unit dose into both nostrils. This makes it easy for the patient or carer who is administering the drug from the device to understand and remember the number of volume unit doses administered at one treatment time. This makes it much more unlikely that more than the prescribed number of doses will be administered and so makes it much more likely that the drug will be administered safely at any one treatment time.

It is recognised that there is a 'tailing-off' problem associated with administration of solutions from a nasal pump dispensing device viz. as the container empties full priming of the pump becomes less reliable; this in turn means that on actuation of the pump the volume of the drug solution dispensed can be less than the volume unit dose of the solution. Typically this means that there is a tendency for a patient or carer to administer an additional dose on realising that a full dose was not initially administered.

This can be a dangerous practice with analgesics of the potency of opioids.

Preferably, the dispenser includes counting means operable to count the number of one volume unit doses administered and further includes dispenser deactivating means which is operated by the counting means to prevent further administration of the drug by the dispenser when the counting means has counted said predefined number of times (N). This number (N) is chosen (bearing in mind the fill volume (Vf) of the solution contained in the container before any doses have been administered) in order to ensure that (N) full doses are administered, i.e. the deactivation means operates to prevent further discharge of solution from the device before the tail off phenomenon is reached.

This contributes to the safe use of the device as it gives to the patient or carer an indication as to the number of doses which have been administered and furthermore prevents administration of any solution remaining in the container after all the predefined number (N) of volume unit doses have been dispensed.

Preferably the predefined number (N) of volume unit doses is chosen to be in the range of 2 to 30, more preferably in the range 3-20, and most preferably the predefined number (N) is in the range 4 to 8.

Various aspects of the present invention are hereinafter described with reference to the accompanying drawings, in which:

Figure 1 is a schematic side view of a device according to a first embodiment of the present invention;

Figures 2A and 2B are, respectively, schematic side views of devices according to the first and second embodiments shown in a tipped condition;

Figures 3A, 3B, and 3C are, respectively, schematic side views of devices according to second, third and forth embodiments of the present invention; and

Figure 4 is a schematic side view of a device according to a fifth embodiment of the invention.

Referring initially to Figure 1 there is shown a nasal dispensing device 10 which includes a closed container 12 and a dispenser 14. An analgesic solution 15 is contained within the container 12.

The dispenser 14 is preferably a dispenser of the type disclosed in US patent 4565302 (the full disclosure being incorporated herein by reference).

The dispenser 14 thereby includes a spray head 16 which is reciprocally mounted on a mounting body 18. The mounting body 18 is fixedly secured to the container 12 to prevent its removal; accordingly access to the solution 15 is not permitted unless it is dispensed via the dispenser 14. The body 18 may be attached to the container 12 by a crimp and snap fitting or a one-way screw fitting in which a ratchet on the body 18 engages with lugs on the container such that the body 18 can only be screwed in one direction only. An example of such a container can be purchased from Saint Gobain Desjonqueres, France.

The dispenser 14 further includes a pump 20 mounted on the mounting body 18. The pump 20 has an inlet (not shown) communicating with a dip tube 22. The dip tube 22 depends from the pump 20 towards the bottom of the container 12 such that its terminal end 23 is located beneath the surface of the solution 15. Accordingly on operation of the pump 20, solution is drawn along the tube 22 into the inlet of the pump 20.

The pump 20 further includes an outlet (not shown) which communicates with a spray nozzle 26 formed on the spray head 16. Accordingly on operation of the pump 20 solution is discharged through the spray nozzle 26 to form a spray 30.

The pump 20 is preferably of the two stroke reciprocating type having a priming chamber in which a pump piston reciprocates; the reciprocal motion of the piston in one direction, i.e. a first stroke of the piston, causing solution contained in the priming chamber to be discharged through the spray nozzle 26 and reciprocal motion of the piston in the opposite direction, i.e. a second stroke of the piston, causing solution to be drawn from the container 12 and into the priming chamber in readiness for the next discharging first stroke.

With such a pump the volume of solution discharged through the nozzle 26 is determined by the volume of the priming chamber. This volume is preferably chosen to be in the range 0.05ml to 0.15ml for the reasons previously mentioned and defines the volume unit dose (Vu) to be dispensed by the device 10. In the embodiment shown in Figure 1 the volume unit dose (Vu) is 0.1ml.

The pump 20 is operably connected to the spray head 16 such that downward depression of the head 16 in the direction of arrows 'O' in Figure 1 causes the pump 20 to discharge the volume unit dose (Vu) of the solution in the form of spray 30.

Preferably, as with the dispenser disclosed in US patent 4565302, the dispenser 14 includes a counting means which is operated each time the pump 20 is operated to dispense a volume unit dose of solution 15. Preferably as indicated in the fifth embodiment of Figure 4, the counting means operates a visual display 34 which indicates to the operative (i.e. the patient or carer) the number of volume unit doses which have been administered from the device 10.

Other examples of electronic and dose counters for pharmaceutical dispensing devices which can be used with the device of the present invention are described in US patents 7347200, 7195134, 6769601, 6659307, 6651844 and 6446627 (the disclosures thereof being incorporated herein by reference).

Preferably as provided by the dispenser of US patent 4565302, the device 10 includes dispenser inactivation means which operates to prevent further discharge of the solution 15 after the predefined number (N) of volume unit doses have been dispensed. As indicated hereinbefore, the number (N) is preferably chosen to ensure that only full volume unit doses of solution are discharged from the device 10 in order to avoid the tail-off phenomenon. This number (N) needs to be chosen bearing in mind the fill volume (Vf) and also the residual volume (Vr) of the solution.

In this respect the minimum fill volume (Vf) of the solution contained in container 12 is given by the equation :

$$Vf = (Vu \times N) + P + Vr$$

Where Vu is the volume unit dose, N is the predefined number of volume unit doses to be administered by the device, P is the volume of solution required to initially prime the pump and fill the dip tube, and Vr is the residual amount of solution remaining in the container 12 after N full volume unit doses have been dispensed from the container 12.

It is recognised that the tail off phenomenon is caused by air entering the terminal end 23 of the dip tube when the container 12 nears to empty and so in accordance with the present invention Vr is chosen to be sufficiently great to maintain the terminal end 23 of

the dip tube 22 submerged beneath the surface of the solution 15 after dispensing a volume unit dose for the Nth time.

Vr should be kept to a minimum in order to avoid unnecessary waste and preferably the volume (Vr) is less than 1ml, more preferably less than 0.8ml and most preferably less than 0.6ml.

In order to achieve volumes (Vr) of this order, the shape of the container 12 is adapted to reduce the volume (Vr) required to ensure that a full final Nth volume unit dose of solution is administered, particularly when bearing in mind that the container 12 is typically angled at about 30 degrees from the vertical when used.

This is illustrated for comparative purposes in Figure 2 wherein the container of Figure 2 A has a much wider internal dimension compared to the container of Figure 2B. It will be appreciated by comparing the containers of Figures 2A and 2B that the container of Figure 2A requires a much larger volume Vr to maintain the tip 23 of dip tube 22 submerged beneath the surface of the solution 15 (particularly when tipped at 30 degrees) than the container of Figure 2B.

Various designs of container 12 according to the present invention are illustrated by way of example in Figures 3A, 3B, and 3C; these containers share the common aim of providing a container having a relatively large external volume to provide stability for the container 12 when placed upon a surface, e.g. table top, whilst providing a reduced internal volume for retaining the solution 15 and thereby reduce volume Vr.

In Figure 3A, the reduced internal volume is achieved by increasing the thickness of the side walls 12a of the container 12.

In Figure 3B, the side walls 12a are also thickened to define an internal volume which is of inverted conical shape. This provides an internal bottom for the container 12a which is only slightly wider than the width of the dip tube 22 and so requires a small volume of solution to submerge the terminal end 23 of the tube 22.

In Figure 3C, the internal volume of the container 12 is defined by a narrow closed tube insert 12b. The internal diameter of the tube insert 12b is slightly greater than the external diameter of the dip tube 22 and so again requires only a small volume Vr to submerge the tip 23 of the dip tube 22.

These preferred shapes of container 12 may be expressed in terms of the 'volume ratio' of the internal volume to the external volume, i.e. if the container has an internal volume of 6ml and external volume of 10ml, then the container would have a volume ration of 0.6.

The internal volume of the container 12 is most conveniently measured by determining the weight of water required to fill the container to the brim and then, using the known density of water, calculating the volume.

The external volume of the container may be determined by measuring the external dimensions of the container and calculating the volume from the measured dimensions, or by measuring the weight of water displaced when the container is fully immersed in water and then using the known density of water to calculate the volume.

Preferably the volume ratio is in the range 0.15 to 0.9, more preferably 0.2 to 0.9, and most preferably 0.25 to 0.7.

The container 12 may be made from glass, plastics or a combination of both, for example a glass bottle with a plastics insert. The preferred plastic is a cyclic olefin copolymer.

The solution 15 contained within the container 12 is preferably an opioid solution which contains as an active component an opioid analgesic in a sufficient concentration to provide the desired therapeutic relief per volume unit dose (Vu).

Typically for a less potent opioid analgesic such as morphine, the amount by weight present in a volume unit dose (Vu) is in the range of 1 to 50 mg whereas for a more potent analgesic such as sufentanil the amount present by weight in a volume unit dose (Vu) is 1 to 200 micrograms.

An especially preferred opioid analgesic for use in the compositions of this invention is fentanyl. Fentanyl (N-(1-phenethyl-4-piperidyl)propionanilide) is a potent opioid analgesic agent used in the treatment of severe acute and chronic pain. By the term fentanyl we include its salts. Fentanyl is generally used in the form of the citrate salt.



Fentanyl

The preferred intranasal dose of fentanyl, expressed as base, for treating a single episode of acute pain is in the range 10 to 2000 micrograms, more preferably 15 to 1500 micrograms, and most preferably 20 to 1000 micrograms. The preferred amount of fentanyl by weight, expressed as base, present in a volume unit dose (Vu) is in the range of 5 to 2000 micrograms.

Example

A preferred example of an intranasal device utilising fentanyl as the opioid analgesic is detailed below:-

(i) Drug solution: The solution is preferably predominantly aqueous and contains 0.1 to 20 mg/ml fentanyl, preferably in the form of the citrate salt, wherein 0.1 mg/ml and 20 mg/ml fentanyl are equivalent to approximately 0.16 mg/ml and 31.4 mg/ml fentanyl citrate, respectively. The drug solution may optionally contain additives well known to one skilled in the art, such as preservatives, agents to adjust tonicity and acids or bases to adjust pH. Viscosity-modifying or gel-forming polymers, such as pectin, chitosan, celluloses or poloxamers may also be included. Examples of fentanyl intranasal compositions suitable for use in this invention may be found in WO 04/062561 and WO 02/09707.

(ii) Volume unit dose (Vu): The volume of each dose spray delivered by actuation of the spray pump is preferably 0.05 ml or 0.1 ml.

(iii) "Volume Ratio": The container preferably has a volume ratio, as defined earlier, in the range 0.3 to 0.7.

(iv) Fill volume (Vf): The bottle fill volume is preferably in the range 0.7 to 3.5 ml, more preferably in the range 0.8 to 3.0 ml, and most preferably in the range 0.9 to 2.5 ml, for example 1.0 to 1.8 ml.

(v) Number of volume unit doses (N): The number of dose sprays is preferably in the range 2 to 30, more preferably in the range 3 to 20, and most preferably in the range 3 to 16, for example 4 to 8.

The dispensing device 12 described above and illustrated in the accompanying drawings is particularly adapted for intranasal administration of the solution 15. It is however appreciated that the device may be adapted by adopting a suitably shaped nozzle instead of spray nozzle 26 to administer opioid analgesics by other routes, such as the oral cavity for buccal or sublingual absorption.

CLAIMS:

1. A device for administering a predefined number (N) of predefined volume unit doses (Vu) of an opioid analgesic in liquid form, the device including a closed container containing a predetermined fill volume (Vf) of the opioid analgesic and a dispenser connected to the container, the dispenser being operable to administer an individual one volume unit dose (Vu) repeatedly said predefined number of times (N), both the dispenser being adapted and the concentration of said opioid analgesic being chosen such that said volume unit dose is in the range 0.05 to 0.15ml.

2. A device according to Claim 1 wherein the volume unit dose is 0.1ml.

3. A device according to Claim 1 wherein the concentration of the opioid analgesic in liquid form is in the range 0.005 mg/ml to 1000 mg/ml.

4. A device according to Claim 3 wherein the opioid analgesic is a solution of fentanyl, the concentration of fentanyl in the solution being in the range of 0.1 to 20 mg/ml.

5. A device according to Claim 4 wherein the solution of fentanyl is a solution of fentanyl citrate, the concentration of fentanyl citrate in the solution being in the range of about 0.16 to 31.4 mg/ml.

6. A device according to any preceding claim wherein said predefined number (N) is in the range 2 to 30.

7. A device according to Claim 6 wherein the predefined number (N) is in the range 4 to 8.

8. A device according to Claim 6 or Claim 7 wherein the dispenser is a nasal spray dispenser including a two-stroke pump which is operable on a complete first stroke in one direction to discharge said unit volume dose and operable on a complete second stroke in the opposite direction to replenish the pump, the pump further including a dip tube which extends into the container in order to feed the liquid analgesic in the container to the pump.

9. A device according to any preceding claim wherein the dispenser includes counting means operable to count the number of one volume unit doses administered and further includes dispenser deactivating means which is operated by the counting means to prevent further administration of the drug by the dispenser when the counting means has counted said predefined number of times (N).

10. A device according to Claim 9 wherein the container has an internal/external volume ratio (as herein defined) in the range of 0.15 to 0.9.

11. A device according to claim 10 wherein the internal/external volume ratio is in the range of 0.25 to 0.7.

12. A device according to any of Claims 9 to 11 wherein the fill volume (Vf) of the opioid analgesic is determined in accordance with the formula

$$Vf = (Vu \times N) + P + Vr$$

wherein P is the volume required for priming the pump and Vr is the residual volume of liquid opioid analgesic remaining in the container at the end of administering volume unit doses N times and which is sufficient to ensure N full volume unit doses are administered.

13. A device for administering a predefined number (N) of predefined volume unit doses (Vu) of an opioid analgesic in liquid form substantially as herein described with reference to the accompanying drawings.



Fig. 1



Fig. 2A



Fig. 2B



Fig. 3A

Fig. 3B

Fig. 3C



Fig. 4

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2009/002288

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61M15/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/13886 A2 (UNIV KENTUCKY RES FOUND [US]; WERMELING DANIEL [US]; VALLANCE RYAN [US) 21 February 2002 (2002-02-21) page 15, last paragraph - page 18, line 5	1-12
X	US 2004/135002 A1 (BELLER KLAUS-DIETER [DE]) 15 July 2004 (2004-07-15) paragraph [0021] - paragraph [0062]	1-8, 10-12
A	US 2007/209660 A1 (WERMELING DANIEL P [US]) 13 September 2007 (2007-09-13) paragraph [0018] - paragraph [0021]	1-5
X	US 6 189 739 B1 (VON SCHUCKMANN ALFRED [DE]) 20 February 2001 (2001-02-20)	1
A	page 3, left-hand column, line 32 - page 8, right-hand column, line 41; figures 1-6	8

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 February 2010	04/03/2010

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Kroeders, Marleen

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 13

Claim 13 defines its subject-matter solely in reference to the drawings of the application, contrary to the requirements of Rule 6.2(a) PCT.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.2), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2009/002288

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 13
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2009/002288

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0213886 A2	21-02-2002	AU 8651801 A	25-02-2002
		EP 1315533 A2	04-06-2003
		JP 2004505730 T	26-02-2004
		US 2003163099 A1	28-08-2003
		US 2006021614 A1	02-02-2006
US 2004135002 A1	15-07-2004	AT 281890 T	15-11-2004
		WO 02087777 A1	07-11-2002
		DE 10121232 A1	07-11-2002
		DK 1390154 T3	14-03-2005
		EP 1390154 A1	25-02-2004
		ES 2232759 T3	01-06-2005
		JP 2004537346 T	16-12-2004
		PT 1390154 E	28-02-2005
US 2007209660 A1	13-09-2007	NONE	
US 6189739 B1	20-02-2001	AU 722098 B2	20-07-2000
		AU 3169397 A	05-01-1998
		BR 9709503 A	10-08-1999
		CA 2256008 A1	11-12-1997
		CN 1220622 A	23-06-1999
		DE 19622124 A1	04-12-1997
		WO 9746324 A1	11-12-1997
		EP 0901406 A1	17-03-1999
		JP 2000511499 T	05-09-2000
		NO 985610 A	01-12-1998
		NZ 333604 A	28-04-2000
		PL 329938 A1	26-04-1999